Clinical effect of recombinant human interferon α-1b atomization therapy in herpes angina in infants
CAO Su1 YAO Huihui2 NIU Feng3▲
1.Department of Pediatrics, 988th Hospital in Chinese People′s Liberation Army Joint Logistics Support Force, He′nan Province, Jiaozuo 454003, China; 2.Outpatient Department, 988th Hospital in Chinese People′s Liberation Army Joint Logistics Support Force, He′nan Province, Jiaozuo 454003, China;
3. Department of Cardiology, 988th Hospital in Chinese People′s Liberation Army Joint Logistics Support Force, He′nan Province, Jiaozuo 454003, China
Abstract:Objective To explore the effect of recombinant human interferon α-1b atomization therapy on herpes angina in infants. Methods From January 2017 to January 2018, 300 infants with herpetic angina in the Jiaozuo Hospital of 988th Hospital in Chinese People′s Liberation Army Joint Logistics Support Force were divided into observation group and control group according to random number table. Children in the control group were given the Ribavirin atomization therapy, and the observation group was given recombinant human interferon α-1b atomization therapy. The effect and drug safety of two groups were analyzed. Results After treatment, the fever abatement time, salivation relief time, herpes subsidence time and hospitalization time of the observation group were significantly shorter than those of the control group (P < 0.01). After treatment, the total effective rate of the observation group was significantly higher than that of the control group (P < 0.05). No obvious adverse reactions were found in the two groups. Conclusion The recombinant human interferon α-1b is effective and safe in the treatment of infantile herpetic angina, and there is significant clinical application value with it.